The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Glutathione-Depleting Nanomedicines for Synergistic Cancer Therapy
Abstract
Cancer cells frequently exhibit resistance to various molecular and nanoscale drugs, which inevitably affects the drugs' therapeutic outcomes. Overexpression of glutathione (GSH) has been observed in many cancer cells, and solid evidence has corroborated the resulting tumor resistance to a variety of anticancer therapies, suggesting that this biochemical characteristic of cancer cells can be developed as a potential target for cancer treatments. The single treatment of GSH-depleting agents can potentiate the responses of the cancer cells to different cell death stimuli; therefore, as an adjunctive strategy, GSH depletion is usually combined with mainstream cancer therapies for enhancing the therapeutic outcomes. Propelled by the rapid development of nanotechnology, GSH-depleting agents can be readily constructed into anticancer nanomedicines, which have shown a steep rise over the past decade. Here, we review the common GSH-depleting nanomedicines which have been widely applied in synergistic cancer treatments in recent years. Some current challenges and future perspectives for GSH depletion-based cancer therapies are also presented. With the understanding of the structure-property relationship and action mechanisms of these biomaterials, we hope that the GSH-depleting nanotechnology will be further developed to realize more effective disease treatments and even achieve successful clinical translations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Photodynamic therapy for cancer
Dolmans, D. E. J. G. J., Fukumura, D., & Jain, R. K. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1071 · Cited by 6,758
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237
Glutathione Metabolism and Its Implications for Health
Wu, G., Lupton, J. R., Turner, N. D., Fang, Y.-Z., & Yang, S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.3.489 · Cited by 3,842
Advances in metal-induced oxidative stress and human disease
Jomova, K., & Valko, M. (2011) · Toxicology · doi:10.1016/j.tox.2011.03.001 · Cited by 3,207
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Gold nanoparticles in delivery applications☆
GHOSH, P., HAN, G., DE, M., KIM, C., & ROTELLO, V (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.016 · Cited by 2,694
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 2,526
In vitro toxicity of nanoparticles in BRL 3A rat liver cells
Hussain, S. M., Hess, K. L., Gearhart, J. M., Geiss, K. T., & Schlager, J. J. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.034 · Cited by 2,025
The importance of glutathione in human disease
Townsend, D. M., Tew, K. D., & Tapiero, H. (2003) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(03)00043-x · Cited by 2,004
Cited by
Chemodynamic Therapy via Fenton and Fenton‐Like Nanomaterials: Strategies and Recent Advances
Jia, C., Guo, Y., & Wu, F. (2022) · Small · doi:10.1002/smll.202103868 · Cited by 685
Self-citationStrategies for enhancing cancer chemodynamic therapy performance
Jana, D., & Zhao, Y. (2022) · Exploration · doi:10.1002/exp.20210238 · Cited by 284
Xu, W., Qian, J., Hou, G., Wang, T., Wang, J., Wang, Y., Yang, L., Cui, X., & Suo, A. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202205013 · Cited by 267
Wang, K., Li, Y., Wang, X., Zhang, Z., Cao, L., Fan, X., Wan, B., Liu, F., Zhang, X., He, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38601-7 · Cited by 253
Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy
Liu, P., Hao, L., Liu, M., & Hu, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1161472 · Cited by 58
A tumor cell exosome-mimicking multifunctional nanozyme for targeted breast cancer radiotherapy
Chen, G., Jiang, D., Ding, S., Huang, C., Zhu, D., & Jiang, H. (2023) · Nanoscale · doi:10.1039/d3nr03065b · Cited by 31
Shi, J., Cui, G., Jin, Y., Mi, B., Liu, K., Zhao, L., Bao, K., Lu, Z., Liu, J., Wang, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402474 · Cited by 18
Wang, Y., Zhao, G., Liu, Y., Wang, R., Xing, Y., Dou, K., & Yu, F. (2025) · Sensors and Actuators B: Chemical · doi:10.1016/j.snb.2024.137005 · Cited by 16
Metadata
- Authors
- Cheng, X., Xu, H.-D., Ran, H.-H., Liang, G., & Wu, F.-G.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-05-11
- Volume
- 15
- Issue
- 5
- Pages
- 8039-8068
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W3162168433
- Cited by
- 374
- References
- 184
- FWCI
- 18.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.